Becker's Healthcare December 23, 2024
On Dec. 23, the FDA approved Hikma Pharmaceuticals’ liraglutide injection, a generic version of Novo Nordisk’s Victoza.
The FDA first approved Victoza in 2010 for Type 2 diabetes, later expanding its use in 2019 as a pediatric, injectable treatment for patients 10 or older. Hikma’s generic includes similar warnings to the brand-name drug, such as risks of thyroid C-cell tumors, pancreatitis, hypoglycemia, kidney failure and acute gallbladder disease.
The injectable GLP-1 is indicated to improve...
Today's Sponsors
Today's Sponsor